Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
PPS EXACTLY where I said it would be....
Who is the KING OF THIS BOARD? Y’all know...EICH KING!
I’ll clue you all in Monday on next closing price...you are all welcome...??
I guess your anti semantic, too.
Well, you see where that got us...
You are SOOO confused.
Your [sic] Narcicism is showing.
Do you realize how [sic] rediculous you sound?!
Is never stopped you. GIDDY UP! We are going to make you and your mini-me work ALL WEEKEND.
Who in their right mind would Ever 'IMAGINE' that ANY of these primary endpoints would ever be "MARKETING" selling points for a Commercial Team!?!!!?!
we get A DO OVER phase III, that 'Hopefully' be powered to 'prevent' instead of just 'delay' Amputations... Amateurs, and Not much has changed.
No kidding Allo... You don't say. I have been saying for months and months. THAT IS WHY THERE IS NO CONTRACT!!!!!! That is why they are still only "TALKING" and NOT shipping, coupled with not enough production to supply with 'vials and syringes" or. "The current delivery system"
First, let me say that it's a pleasure to have a disagreement and remain civil and make a point without rancor.
A challenge to ones assumptions is always healthy, and it's good to test and retest your investment thesis as facts unfold.
You cannot deny that the stock has been in a long term downtrend for several years. They don't reverse on a dime as it takes time to reverse the damage.
it [the market?] seems to be sniffing out some news now unknown to most that could derail the whole "promise to come".
Imagine that....$1.22.....hmmmm....how'd he do that Scooby?
So far, they cannot close a deal with ....
When the Friday close comes @ $1.22 (ooops...or today)....
$1.22 by EOD tomorrow.......bank on it.
Zzaat- I'm troubled by Auto 1's post#16361.
Based on the date,content attached in the link, can you refute the implications of it.
He implies it's been 8 yrs since they announced they'd be going into Phase 2, and nothing after 8 years has been announced.
What's your take to balance this ominous implication.
What's your take to balance this ominous implication.
PSTI is sinking like a rock. I hate to say this but Eich/Auto seems to be more right than wrong in this "Year of the Shareholder"
I hate to say this but Eich/Auto seems to be more right than wrong
Before you celebrate your "victory" (LOL!) read below! The import of the article is that they still (2018) do not know the exact cause (now, you need to read carefully, pay attention to detail, they're significant).
Just a note: PLURISTEM IS NOT DOING PREECLAMPSIA,PLURISTEM IS NOT DOING PREECLAMPSIA,PLURISTEM IS NOT DOING PREECLAMPSIA,PLURISTEM IS NOT DOING PREECLAMPSIA,PLURISTEM IS NOT DOING PREECLAMPSIA,PLURISTEM IS NOT DOING PREECLAMPSIA,ETC.
BTW, have you done research on how authors get funding (among others): it's.... CONSULTING FEES !!
From the Preeclampsia Foundation (the latest):
CAUSE OF PREECLAMPSIA
Preeclampsia was once called “the disease of theories,” but research efforts this past decade have produced exciting breakthroughs that may bring us closer to causality, improve diagnosis and even prediction, and lead to prevention and/or specific treatments. Some speculation remains over different theories including: changes in biology of the placenta, the systemic inflammatory response, a variety of hormones and other proteins that are in the mother’s circulation, changes in immune factors, improper cardiovascular adaptations to the pregnant state, underlying maternal risks for cardiovascular disease, associations with insulin resistance and diabetes, and deficiencies in essential nutrients, minerals, and vitamins.
(note below: "the initiating cause")
The most plausible theories focus on the placenta and describe the disorder in two stages. In the first, the initiating cause results in the placenta producing factors (e.g., specific proteins, placental “debris”) that enter the maternal circulation and are believed responsible for producing the next stage. This is the second stage, which results in the overt maternal “disease” (high blood pressure, kidney, liver and coagulation abnormalities). The overt disease depends not only on the action of the circulating factors from the placenta, but also the health of the mother, including diseases that may affect the vasculature (such as preexisting cardiovascular, renal, metabolic, and genetic factors; and obesity). A quick chart of potential causes can be found in our FAQs.
A promising area of recent research involves the role of proteins produced by the placenta that inhibit angiogenesis (the production of new blood vessels). Two of these “antiangiogenic factors” (soluble Fms-like tyrosine kinase-1, and soluble endoglin) have been shown to produce a preeclampsia like disease in rodents. Their concentrations rise in the mother’s circulation weeks to months before the disease manifests. Placentas of women destined to develop preeclampsia overproduce these proteins that then enter the mother’s circulation. Neutralizing their actions is now being investigated in animal models, and in some studies has reversed the disease in rodents. . Excitement regarding these interventions is tempered by a limited understanding of the functional role of antiangiogenic substances in normal pregnancy.
If the ability of these antiangiogenic proteins to cause preeclampsia is confirmed by research in humans, why the placenta overproduces them remains unknown. Hence, many of the other areas of investigation mentioned above may be important. Preeclampsia may have multiple causes, and other leads are being investigated, including prostaglandins, digoxin-like molecules, immunological mechanisms, autoantibodies that trigger receptors that lead to vessel constriction (agonistic autoantibodies to the angiotensin 1 receptor), oxidative stress, mitochondrial pathology, the impact of hypertension and prehypertension on endovascular health, and genes sensitive to low oxygen environments.
Basic research into causes of preeclampsia, lacking for decades, is being revitalized, albeit more slowly than needed. While we are moving closer to historically elusive answers, the true cause of preeclampsia remains unknown. Successful ongoing research needs far more support and funding.
The Placenta is the core of Preeclampsia complications.
You didn't answer my question. Since you seem to be speaking for the company:
Since you seem to be speaking for the company:
... Do you work for them?
...and a simple PR updating where preeclampsia has gone would suffice
BTW, the addressing of this individual by first name also shows familiarity....as if they know each other...or work with each other....hmmmmm
....boiler room 101
They Will Never Understand The Concept Of Priorities !
Preeclampsia is in the PSTI abyss, never to be heard from again......well that is until failures are reported on the "current strategy"...What a complete joke. I'd like to know the SPECIFIC question sent to them. Why didn't she expound on preeclampsia?
Preeclampsia obsession continues!!
It's utterly irrelevant. PLX technology is very flexible, and has wide applicability! That's good! AutoEich cannot seem to comprehend the simple notion that Pluristem cannot do EVERYTHING at once. That's bad! How does one explain the obvious.
DO THE MATH over Time, $3-5Billion (at a minimum) left on the table by shelving these early ODD's. IT MAKES NO SENSE! - This is NOT brining shareholder value.
From Dr.Caplan's paper, Cell-Based Therapies:
(thanks for the link Allo!)
Estimates of the number of patients provided MSCs range from 10,000 to over 70,000 with no reported MSC-related serious adverse events warranting shutting down any trials
I'm reposting this from Dr.Caplan's paper (BTW, he's the discoverer and pioneer in MSC science). The implications for approval cannot be over-emphasized. Safety is an absolutely primary consideration for approval, and MSCs look pretty damn good. Bodes well for Pluristem getting FDA approval with any significant improvement in patient's condition.
Why can't preeclampsia be included....
The company response, which clearly ignored the status of preeclampsia is nothing short of very low expectations
Hi PLX, thanks for the report. I have always found Karine very helpful and responsive.
(I can just hear it now: 'but they're not working on "Hamburger's Disease"')
Strange that AutoEich ask all these "logical" questions from you and others on the board, but can't reach out to the company.
As expected, the obvious answer is that Pluristem can't do EVERYTHING, so they have to chose SOMETHINGs, which means that OTHER THINGS will not be done in parallel.
I think this is a very interesting point in Dr.Kleinhaus' response.
"The platform technology can make multiple PLX products each of which can work in several indications"
The safety of MSCs as a therapeutic modality is being established (see below) and the (somewhat) general nature of the paracrine response will make off label use for related syndromes very tempting.
From Dr.Caplan's paper, Cell-Based Therapies:
(thanks for the link Allo!)
Estimates of the number of patients provided MSCs range from 10,000 to over 70,000 with no reported MSC-related serious adverse events warranting shutting down any trials
My expectation is that once we get one approval (CLI I hope), there will be an avalanche of new uses for similar indications (radiation is the prime example for that, also muscle damage from trauma, etc.)
Response to Eich:
Comparing a government funded project to the moon, which never had a goal of profitability is not a valid comparison
To say shareholders that got in 18 years ago got in too early is preposterous. Without those shareholders, PSTI wouldn't even exist.
Your [Auto] questions are valid
The best I can do is compose something to Ms. Kleinhaus. I'll let you know if I get a response.
Very relevant and very shady IMO.
$1.28....exactly as I said. I must either be omniscient or a genius.....
Previously, you stated something incoherent about going to the moon and the process, comparing it to PSTI...
Survey says........wrong. Managements most important job is to return value to shareholders.....end of story...
...18 years of bleeding shareholders, is BK coming
Indications and partnerships in countries that fell into the abyss.
I believe PSTI's management is completely culpable in their promises...like preeclampsia in 2016...